Large-scale analysis of DNA methylation in chronic lymphocytic leukemia

Epigenomics

Volumn 1, Issue 1, 2009, Pages 39-61

  Rahmatpanah, Farahnaz B ^a   Carstens, Stephanie ^a   Hooshmand, Sam I ^a   Welsh, Elise C ^a   Sjahputera, Ozy ^a   Taylor, Kristen H ^a   Bennett, Lynda B ^a   Shi, Huidong ^a   Davis, J Wade ^a   Arthur, Gerald L ^a   Shanafelt, Tait D ^a   Kay, Neil E ^a   Wooldridge, James E ^a   Caldwell, Charles W ^a  

^a University of Missouri   (United States)

Author keywords

CD38 expression; CLL; DNA methylation; Epigenetics; Leukemia

Indexed keywords

ADAM 12 PROTEIN; ADAM PROTEIN; CD38 ANTIGEN; DLEU7 PROTEIN, HUMAN; DNA; MEMBRANE PROTEIN; NEUROPILIN 2; SFRP2 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLUSTER ANALYSIS; CPG ISLAND; DNA METHYLATION; DNA MICROARRAY; DNA SEQUENCE; GENE LOCUS; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE;

ADAM PROTEINS; ANTIGENS, CD38; CELL LINE, TUMOR; CLUSTER ANALYSIS; CPG ISLANDS; DNA; DNA METHYLATION; EPIGENESIS, GENETIC; GENETIC LOCI; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MEMBRANE PROTEINS; MIDDLE AGED; NEUROPILIN-2; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEINS;

EID: 77954126563     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.09.10     Document Type: Article

References (54)

1. Zent CS, Kay NE: Chronic lymphocytic leukemia: biology and current treatment. Curr. Oncol. Rep. 9, 345-352 (2007). (Pubitemid 47377065)
2. Krober A, Seiler T, Benner A et al.: V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100, 1410-1416 (2002). (Pubitemid 34864299)
3. Damle RN, Wasil T, Fais F et al.: IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94, 1840-1847 (1999). (Pubitemid 29430399)
4. Gentile M, Mauro FR, Calabrese E et al.: The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. Br. J Haematol. 130, 549-557 (2005). (Pubitemid 43899758)
5. Eisele L, Haddad T, Sellmann L., Duhrsen U, DurigJ: Expression levels of CD38 on leukemic B cells but not on non-leukemic T cells are comparably stable over time and predict the course of disease in patients with chronic lymphocytic leukemia. Leuk. Res. 33, 775-778 (2009).
6. Hamblin TJ, Orchard JA, Ibbotson RE et al.: CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99 1023-1029 (2002). (Pubitemid 34525567)
7. Tobin G, Rosenquist R: Prognostic usage of VH gene mutation status and its surrogate markers and the role of antigen selection in chronic lymphocytic leukemia. Med. Oncol. 22, 217-228 (2005). (Pubitemid 41176317)
8. Pittner BT, Shanafelt TD, Kay N.E., Jelinek DF: CD38 expression levels in chronic lymphocytic leukemia B cells are associated with activation marker expression and differential responses to interferon stimulation. Leukemia 19, 2264-2272 (2005). (Pubitemid 41741623)
9. Rahmatpanah FB, Carstens S, Guo J et al.: Differential DNA methylation patterns of small B-cell lymphoma subclasses with different clinical behavior. Leukemia 20, 1855-1862 (2006). (Pubitemid 44574996)
10. Caldwell CW, Patterson WP: Relationship between CD45 antigen expression and putative stages of differentiation in B-cell malignancies' Am. J. Hematol. 36, 111-115 (1991).
11. Estecio MR, Yan PS, Ibrahim AE et al.: High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Res. 17, 1529-1536(2007). (Pubitemid 47529437)
12. Walter SD: Point estimation of the odds ratio in sparse 2×2 contingency tables. In: Biostatistics. MacNeill IB, Umphrey GJ, Reidel D (Eds.), 71-102 (1987)
13. Taylor KH, Kramer RS, Davis JW et al.: Ultradeep bisulfite sequencing analysis of DNA methylation patterns in multiple gene promoters by 454 sequencing. Cancer Res. 67, 8511-8518(2007). (Pubitemid 47437425)
14. Rassenti LZ, Jain S, Keating MJ et al.: Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 112, 1923-1930 (2008).
15. Lu D, Zhao Y, Tawatao R et al.: Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 101, 3118-3123 (2004). (Pubitemid 38327744)
16. Dennis Jr. G, Sherman BT, Hosack DA et al.: DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 4, 3(2003).
17. Wahlfors J, Hiltunen H, Heinonen K., Hamalainen E, Alhonen L, Janne J: Genomic hypomethylation in human chronic lymphocytic leukemia. Blood 80, 2074-2080 (1992).
18. Upsanen V, Leinonen P, Alhonen L., Janne J: Hypomethyl ation of ornithine decarboxylase gene and erb-Al oncogene in human chronic lymphatic leukemia. Blood 11, 2042-2044 (1988). (Pubitemid 19030896)
19. Yuille MR, Condie A, Stone EM et al.: TCL1 is activated by chromosomal rearrangement or by hypomethyl ation. Genes Chromosomes cncer 30, 336-341 (2001). (Pubitemid 32216324)
20. Hanada M, Delia D, Aiello A., Stadtmauer E, Reed JC: BCL-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 82, 1820-1828 (1993). (Pubitemid 23278773)
21. Raval A, Tanner SM, Byrd JC et al.: Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 129, 879-890 (2007). (Pubitemid 46813150)
22. Rush LJ, Raval A, Funchain P et al.: fcpigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res. 64, 2424-2433 (2004). (Pubitemid 38523896)
23. Deaglio S, Vaisitti T, Aydin S et al.: CD38 and 2AP-70 are functionally linked and mark CLL cells with high migratory potential. Blood 110, 4012-4021 (2007). (Pubitemid 350248457)
24. Damle RN, Temburni S, Calissano C et al.: CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 110, 3352-3359 (2007). (Pubitemid 350106329)
25. Deaglio S, Vaisitti T, Bergui L et al.: CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood 105, 3042-3050 (2005).
26. Malavasi F, Deaglio S, Ferrero E et al.: CD38 and CD157 as receptors of the immune system: a bridge between innate and adaptive immunity. Mol. Med. 12(11-12), 334-341(2006). (Pubitemid 46489829)
27. Morabito F, Mangiola M, Stelitano C., Deaglio S, Callea V, Malavasi F: Simultaneous expression of CD38 and its ligand CD31 by chronic lymphocytic leukemia B-cells: anecdotal observation or pathogenetic hypothesis for the clinical outcome? Haematologica 88, 354-355 (2003).
28. Moreno-Garcia M.E., Lopez-Bojorques LN, Zentella A., Humphries LA, Rawlings DJ, Santos-Argumedo L: CD38 signaling regulates B lymphocyte activation via a phospholipase C (PLC)-y 2-independent, protein kinase C, phosphatidylcholine-PLC, and phospholipase D-dependent signaling cascade. J. Immunol. 174, 2687-2695 (2005). (Pubitemid 40279683)
29. Batra S, Shi Y, Kuchenbecker KM et al.: Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. Biochem. Biophys. Res. Commun. 342, 1228-1232 (2006).
30. Chim CS, Pang R, Fung T.K., Choi CL, Liang R: Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia 21, 2527-2536 (2007). (Pubitemid 350148897)
31. Dhir M, Montgomery EA, Glockner SC et al.: Epigenetic regulation of WNT signaling pathway genes in inflammatory bowel disease (IBD) associated neoplasia. J. Gastrointest. Surg. 12, 1745-1753 (2008).
32. Gelebart P, Anand M, Armanious H et al.: Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma. Blood 112, 5171-5179(2008).
33. Khan NI, Bendall LJ: Role of WNT signaling in normal and malignant hematopoiesis. Histol. Histopathol. 21, 761-774 (2006). (Pubitemid 44082718)
34. Martin V, Agirre X, Jimenez-Velasco A et al.: Methylation status of Wnt signaling pathway genes affects the clinical outcome of Philadelphia-positive acute lymphoblastic leukemia. Cancer Sci. 99(9), 1865-1868 (2008).
35. Qiang YW, Endo Y, Rubin J.S., Rudikoff S: Wnt signaling in B-cell neoplasia. Oncogene 22, 1536-1545 (2003). (Pubitemid 36390603)
36. Roman-Gomez J., Jimenez-Velasco A, Cordeu L et al.: WNT5A, a putative tumour suppressor of lymphoid malignancies, is inactivated by aberrant methylation in acute lymphoblastic leukaemia. Eur. J. Cancer 43, 2736-2746 (2007). (Pubitemid 350161849)
37. Schmidt M, Sievers E, Endo T., Lu D, Carson D, Schmidt-Wolf IG: Targeting Wnt pathway in lymphoma and myeloma cells. Br. J. Haematol. 144(5), 796-798 (2008).
38. Sengupta A, Banerjee D, Chandra S et al.: Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression. Leukemia 21, 949-955 (2007). (Pubitemid 46672071)
39. Wohrle S, Wallmen B, Hecht A: Differential control of Wnt target genes involves epigenetic mechanisms and selective promoter occupancy by T-cell factors. Mol. Cell Biol. 27, 8164-8177 (2007). (Pubitemid 350234231)
40. Chim CS, Fung TK, Wong KF Lau JS, Liang R: Infrequent Wnt inhibitory factor-1 (Wif-1) methylation in chronic lymphocytic leukemia. Leuk. Res. 30(9), 1135-1139 (2006). (Pubitemid 44037081)
41. Chim CS, Pang R, Liang R: Epigenetic dysregulation of the Wnt signalling pathway in chronic lymphocytic leukaemia. J. Clin. Pathol. 61, 1214-1219 (2008).
42. Howe D, Bromidge T: Variation of LEF-1 mRNA expression in low-grade B-cell non-Hodgkin's lymphoma. Leuk. Res. 30, 29-32 (2006). (Pubitemid 41654701)
43. Liu TH, Raval A, Chen S.S., Matkovic JJ, Byrd JC, Plass C: CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia. Cancer Res. 66, 653-658 (2006). (Pubitemid 43165926)
44. Raval A, Lucas DM, Matkovic JJ et al.: TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J. Clin. Oncol. 23, 3877-3885 (2005). (Pubitemid 46218690)
45. Jin G, Lu D, Yao S et al.: Amide derivatives of ethacrynic acid: synthesis and evaluation as antagonists of Wnt/p-catenin signaling and CLL cell survival. Bioorg. Med. Chem. Lett. 19, 606-609 (2009).
46. Geretti E, Shimizu A, Klagsbrun M: Neuropilin structure governs VEGF and semaphorin binding and regulates angiogenesis. Angiogenesis. 11, 31-39 (2008).
47. Kay NE: Angiogenesis revisited in CLL. Leuk. Res. 31, 1459-1460 (2007). (Pubitemid 47632795)
48. Molica S, Cutrona G, Vitelli G et al.: Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia. Leuk. Res. 31, 1575-1578 (2007). (Pubitemid 47632791)
49. Hammarsund M, Corcoran MM, Wilson W et al.: Characterization of a novel B-CLL candidate gene - DLEU7- located in the 13ql4 tumor suppressor locus. FEBS Lett. 556(1-3), 75-80 (2004). (Pubitemid 38058558)
50. Heisler LE, Torti D, Boutros PC et al.: CpG Island microarray probe sequences derived from a physical library are representative of CpG Islands annotated on the human genome. Nucleic Acids Res. 33, 2952-2961 (2005). (Pubitemid 41511234)
51. Laux DE, Curran EM, Welshons W.V., Lubahn DB, Huang TH: Hypermethylation of the Wilms' tumor suppressor gene CpG island in human breast carcinomas. Breast Cancer Res. Treat. 56, 35-43 (1999). (Pubitemid 29435813)
52. Garcia-Manero G., Kantarjian HM, Sanchez-Gonzalez B et al.: Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 108, 3271-3279 (2006).
53. Issa JP: Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection. Nat. Clin. Pract. Oncol. 2 (Suppl. 1), S24-S29 (2005).
54. Flotho C, Claus R, Batz C et al.: The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 23, 1019-1028 (2009).